Please provide your email address to receive an email when new articles are posted on . Valgimigli is deputy chief of interventional cardiology at Cardiocentro Ticino Institute, Lugano, Switzerland.

When stopping dual antiplatelet therapy (DAPT) after PCI, it appears that a P2Y12 inhibitor is a better option than aspirin for continuing monotherapy, a network-meta-analysis suggests. The risk of MI ...

BARCELONA -- Patients with documented coronary artery disease (CAD) saw cardiovascular benefits with P2Y12-inhibitor monotherapy when compared with aspirin alone, according to the PANTHER ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Long-term P2Y12 inhibition after PCI reduced bleeding at ...

Giving a P2Y12 inhibitor anti-clotting drug to patients with coronary artery disease is associated with lower rates of cardiovascular death, heart attack and stroke compared with traditional aspirin, ...

A major international study has found that heart patients, particularly seniors, may benefit more from newer blood-thinning medications called P2Y12 inhibitors than traditional aspirin therapy ...

Compared with those assigned to aspirin, patients assigned to a P2Y12 inhibitor had a lower net composite of adverse cardiac and cerebrovascular events. HealthDay News — For patients who undergo ...

The medical and research communities continue to refine what works and what doesn’t in COVID-19, and joining the latter group are two new trials targeting the inflammatory and thrombotic risks of the ...

A P2Y12 inhibitor, such as clopidogrel or ticagrelor, might be a better choice than aspirin for antiplatelet monotherapy in patients with coronary artery disease, results of a new meta-analysis ...

"This analysis along with other recent data suggest P2Y12 inhibitor monotherapy is the preferred antiplatelet approach for secondary prevention and is better than aspirin."—Michael C. McDaniel, MD, ...

Data on CAY001, a First-in-Class, Polyphosphate (polyP)-Based Therapy, Show Promise in Bypassing P2Y12 Inhibition to Restore Normal Clotting Function These early data are promising as they demonstrate ...